Atezolizumab (Tecentriq) for Mesothelioma

Atezolizumab, marketed as Tecentriq, is a PD-L1 immune checkpoint inhibitor that is being investigated as a treatment for malignant pleural mesothelioma. Unlike PD-1 inhibitors such as nivolumab and pembrolizumab, which block the PD-1 receptor on T cells, atezolizumab works by binding directly to PD-L1 (programmed death-ligand 1) on the surface of tumor cells, preventing the tumor from deactivating attacking immune cells.¹

The rationale for using atezolizumab in mesothelioma is based on the observation that many mesothelioma tumors express high levels of PD-L1 — a protein that cancer cells use to evade immune destruction. By blocking PD-L1, atezolizumab unmasks the tumor to the immune system, allowing T cells to recognize and attack mesothelioma cells. While the drug is not yet FDA-approved specifically for mesothelioma, clinical trials have shown encouraging results, particularly when used as switch maintenance therapy after first-line chemotherapy.²

The most notable mesothelioma trial for atezolizumab is the DREAM study (Durvalumab and atezolizumab were both evaluated in separate studies, but the DREAM trial specifically studied atezolizumab as switch maintenance). This Australian phase II trial enrolled patients with unresectable malignant pleural mesothelioma who had not progressed after 4–6 cycles of platinum/pemetrexed chemotherapy. Results showed that maintenance atezolizumab extended median progression-free survival and demonstrated durable responses in a subset of patients.²

Atezolizumab has also been evaluated in combination with bevacizumab and chemotherapy for mesothelioma, following the success of this approach in non-small cell lung cancer (the IMpower150 trial). Research is ongoing to determine whether the addition of anti-angiogenic agents can enhance the immune response in mesothelioma.³

Atezolizumab is being studied in several treatment strategies for mesothelioma, though it has not yet received FDA approval for this indication:²

Switch Maintenance After Chemotherapy

The DREAM trial evaluated atezolizumab as switch maintenance — starting immunotherapy immediately after completing first-line chemotherapy rather than waiting for disease progression:²

• Eligibility — Patients who completed 4–6 cycles of platinum/pemetrexed without disease progression
• Dosing — Atezolizumab 1200 mg intravenously every 3 weeks
• Duration — Continued until disease progression or unacceptable toxicity
• Results — Median progression-free survival of 8.4 months from start of maintenance; 1-year PFS rate of 36%

Combination With Bevacizumab

Studies are investigating atezolizumab combined with bevacizumab (anti-VEGF therapy), based on evidence that anti-angiogenic agents can enhance anti-tumor immunity by normalizing tumor vasculature and improving T-cell infiltration:³

• Rationale — Bevacizumab may reprogram the immunosuppressive tumor microenvironment, making immunotherapy more effective
• Precedent — The IMpower150 trial showed significant survival benefit with atezolizumab + bevacizumab + chemotherapy in lung cancer

How Atezolizumab Differs From Other Checkpoint Inhibitors

Atezolizumab targets PD-L1 on the tumor rather than PD-1 on T cells, which may preserve the PD-L2/PD-1 interaction and potentially reduce certain immune-related side effects. Clinically, the side effect profile is similar to other checkpoint inhibitors, though subtle differences in efficacy and tolerability across tumor types are still being studied.¹

Clinical trial data for atezolizumab in mesothelioma shows promising activity, particularly in the maintenance setting:²

• DREAM trial maintenance — Median PFS of 8.4 months from start of maintenance atezolizumab; 1-year overall survival rate of approximately 65%
• Durable responses — A subset of patients achieve long-lasting responses that continue beyond one year, suggesting meaningful benefit for selected patients
• PD-L1 expression — Higher PD-L1 expression on tumor cells may predict better response, though this biomarker is not definitive for patient selection
• Ongoing research — Phase III trials are needed to confirm the survival benefit of maintenance atezolizumab and identify the patients most likely to benefit

Atezolizumab's side effects differ from traditional chemotherapy because they are driven by immune system activation rather than direct cell toxicity:¹

• Fatigue — The most common side effect, affecting 30–40% of patients. Usually mild to moderate and manageable with activity modification
• Immune-related adverse events (irAEs) — The immune system may attack normal tissues, causing inflammation in various organs. Common irAEs include skin rash (20%), thyroid dysfunction (10–15%), and hepatitis (5–10%)
• Pneumonitis — Immune-mediated lung inflammation occurs in 2–5% of patients and requires prompt recognition. Report any new cough, shortness of breath, or chest pain immediately
• Colitis — Immune-related diarrhea or colitis occurs in 5–10% of patients. Mild diarrhea can be managed with loperamide, but persistent or bloody diarrhea requires urgent medical attention and possible corticosteroid treatment
• Endocrine disorders — Thyroid dysfunction (hypothyroidism or hyperthyroidism) is common and usually manageable with hormone replacement. Adrenal insufficiency and type 1 diabetes are rare but serious complications
• Infusion reactions — Mild reactions (fever, chills, flushing) may occur during the first few infusions and typically resolve with slowing the infusion rate